Citations

Clear

16280 citation(s) found for "Yu, David".

The Role of Lipoprotein A-I and Lipoprotein A-I/A-II in Predicting Coronary Artery Disease
Nguyen, T. T. , Hallaway, Brenda J., Hodge, David O. , Bailey, Kent R. , Holmes, David R. , Kottke, B A, O’Brien, Timothy

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | June 17, 2011 | Volume: 15 | Issue: 2 | Pages: 228-231

10.1161/01.atv.15.2.228 | PMID 7749830 Get It

Abstract The aim of this study was to examine the role of HDL subparticles with apolipoprotein (apo) A-I alone (LpA-I) and with apoA-I and apoA-II (LpA-I/A-II) in predicting coronary artery disease. Concentrations of these HDL subparticles were compared in 184 subjects with angiographically confirmed significant coronary artery disease (>50% stenosis of at least one vessel) and 191 age- and sex-matched control subjects without clinical coronary artery disease. LpA-I and LpA-I/A-II were measured with magnetic beads coated with anti–apoA-II antibodies to separate particles containing apoA-II from plasma. Total plasma cholesterol and triglyceride levels were similar in both groups. Although subjects with coronary artery disease had lower HDL cholesterol, plasma apoA-I, LpA-I, and LpA-I/A-II than age- and sex-matched control subjects without coronary artery disease, plasma apoA-I was the best predictor of coronary artery disease. In conclusion, LpA-I and LpA-I/A-II are lower in subjects with coronary artery disease but do not add to plasma apoA-I in predicting the presence of coronary artery disease.
Cerebrovascular Manifestations in 321 Cases of Hereditary Hemorrhagic Telangiectasia
Maher, Cormac O. , Piepgras, David G., Brown, Robert D., Friedman, Jonathan A., Pollock, Bruce E.

Mayo Clinic

Stroke | June 17, 2011 | Volume: 32 | Issue: 4 | Pages: 877-882

10.1161/01.str.32.4.877 | PMID 11283386 Get It

Background and Purpose —Patients with hereditary hemorrhagic telangiectasia (HHT) are at risk for developing cerebral vascular malformations and pulmonary arteriovenous fistulae. We assessed the risk of neurological dysfunction from these malformations and fistulae. Methods —Three hundred twenty-one consecutive patients with HHT seen at a single institution over a 20-year period were studied. Any evidence of prior neurological symptoms or presence of an intracranial vascular malformation was recorded. All cases of possible cerebral arteriovenous malformation were confirmed by conventional arteriography. Results —Twelve patients (3.7%) had a history of cerebral vascular malformations. Ten patients had arteriovenous malformations, 1 had a dural arteriovenous fistula, and 1 had a cavernous malformation. Seven patients (2.1%) presented with intracranial hemorrhage, 2 presented with seizures alone, and 3 were discovered incidentally. The average age at the time of symptomatic intracranial hemorrhage was 25.4 years. All patients with a history of intracranial hemorrhage were classified as Rankin grade I or II at a mean follow-up interval of 6.0 years. A history of cerebral infarction or transient ischemic attack was found in 29.6% of patients with HHT and a pulmonary arteriovenous fistula. Conclusions —The risk of intracranial hemorrhage is low among people with HHT. Furthermore, a majority of these patients have a good functional outcome after hemorrhage. The data do not suggest a compelling indication for routine screening of patients with HHT for asymptomatic cerebral vascular malformations. By comparison, pulmonary arteriovenous fistulae are a much more frequent cause of neurological symptoms in this population.
Ischemic Stroke Subtypes
Petty, George W., Brown, Robert D. , Whisnant, Jack P., Sicks, JoRean D. , O’Fallon, W. Michael, Wiebers, David O.

Mayo Clinic

Stroke | June 17, 2011 | Volume: 30 | Issue: 12 | Pages: 2513-2516

10.1161/01.str.30.12.2513 | PMID 10582970 Get It

Background and Purpose —There is scant population-based information on incidence and risk factors for ischemic stroke subtypes. Methods —We identified all 454 residents of Rochester, Minn, with a first ischemic stroke between 1985 and 1989 from the Rochester Epidemiology Project medical records linkage system. We used Stroke Data Bank criteria to assign infarct subtypes after reviewing medical records and brain imaging. We adjusted average annual incidence rates by age and sex to the US 1990 population and compared the age-adjusted frequency of stroke risk factors across ischemic stroke subtypes. Results —Age- and sex-adjusted incidence rates (per 100 000 population) were as follows: large-vessel cervical or intracranial atherosclerosis with >50% stenosis, 27; cardioembolic, 40; lacuna, 25; uncertain cause, 52; other or uncommon cause, 4. Sex differences in incidence rates were detected only for atherosclerosis with stenosis (47 [95% CI, 34 to 61] for men; 12 [95% CI, 7 to 17] for women). There was no difference in prior transient ischemic attack and hypertension among subtypes, and diabetes was not more common among patients with lacunar infarction than other common subtypes. Conclusions —The age-adjusted incidence rate of stroke due to stenosis of the large cervicocephalic vessels is nearly 4 times higher for men than for women. There is no association between preceding transient ischemic attack and stroke mechanism. Diabetes and hypertension are not more common among patients with lacunae. Age- and sex-adjusted incidence rates for ischemic stroke subtypes in this population can be compared with similarly determined rates from other populations.
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
Madan, Sumit , Lacy, Martha Q. , Dispenzieri, Angela , Hayman, Suzanne R. , Detweiler‐Short, Kristen, Dingli, David , Zeldenrust, Steven R., Lust, John A., Greipp, Philip R., Rajkumar, S. Vincent , Kumar, Shaji , Gertz, Morie A. , Buadi, Francis K. , Rajkumar, S Vincent , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | June 15, 2011 | Volume: 118 | Issue: 7 | Pages: 1763-1765

10.1182/blood-2011-04-350009 | PMID 21673347 Get It

AbstractThe efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58%) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repeat IMiD (thalidomide [34; 24%] or lenalidomide [106; 76%]) as one of the salvage regimens. A median of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were administered before IMiD-based salvage therapy. The median time from diagnosis to repeat exposure to IMiD was 28 months. Among the 113 evaluable patients, 50 (44%) achieved at least a partial response, and 63 (56%) achieved less than a partial response to repeat IMiD. Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide.
DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment
Kantarci, Kejal , Petersen, R. C., Boeve, B. F., Knopman, David S., Weigand, Stephen D. , O’Brien, Peter C. , Shiung, Maria M., Ivnik, Robert J., Tangalos, E. G., Jack, Clifford R. , Smith, Glenn E. , Jack, Clifford R , Kantarci, Kejal

Mayo Clinic

Neurology | June 14, 2011 | Volume: 64 | Issue: 5 | Pages: 902-904

10.1212/01.wnl.0000153076.46126.e9 | PMID 15753434 Get It

APOE genotype and cognitive decline in a middle-aged cohort
Blair, Cindy K. , Folsom, Aaron R. , Bray, Molly S., Boerwinkle, Eric , Knopman, David S. , Mosley, Thomas H.

Mayo Clinic

Neurology | June 14, 2011 | Volume: 64 | Issue: 2 | Pages: 268-276

10.1212/01.wnl.0000149643.91367.8a | PMID 15668424 Get It

Volume analysis of outcome following restorative proctocolectomy (Br J Surg 2011; 98: 408–417)
Beddy, David, Pembérton, John H.

Mayo Clinic

British Journal of Surgery | June 14, 2011 | Volume: 98 | Issue: 7 | Pages: 1031-1031

10.1002/bjs.7606 | PMID 21618488 Get It

Abstract The Editors welcome topical correspondence from readers relating to articles published in the Journal. Responses should be sent electronically via the BJS website (http://www.bjs.co.uk). All letters will be reviewed and, if approved, appear on the website. A selection of these will be edited and published in the Journal. Letters must be no more than 250 words in length.
Cell Plasticity in Lung Injury and Repair: Report from an NHLBI Workshop, April 19–20, 2010
Borok, Zea , Whitsett, Jeffrey A. , Bitterman, Peter B. , Kotton, Darrell N. , Reynolds, Susan D. , Krasnow, Mark A. , Bianchi, Diana W. , Hogan, Brigid L.M. , Kurie, Jonathan M., Walker, David C., Nishimura, Steve L., Violette, Shelia M., Noble, Paul W. , Shapiro, Steve D., Blaisdell, Carol J., Chapman, Harold A. , Thannickal, Victor J. , Morrisey, Edward E. , Kurie, Jonathan M. , Radisky, Derek C. , Nishimura, Steven L.

Mayo Clinic

Proceedings of the American Thoracic Society | June 8, 2011 | Volume: 8 | Issue: 3 | Pages: 215-222

10.1513/pats.201012-067cb | PMID 21653526 Get It

Abstract In April 2010, a NIH workshop was convened to discuss the current state of understanding of lung cell plasticity, including the responses of epithelial cells to injury, with the objectives of summarizing what is known, what the field needs to know, and how to get there. The proximal stimulus for this workshop is the body of recent evidence suggesting that plasticity is a prominent but incompletely characterized property of lung epithelial cells, and that a focus on understanding this aspect of epithelial cell biology in particular, may be an important window into disease pathobiology and pathogenesis. In addition to their many vital functions in maintaining tissue homeostasis, epithelial cells have emerged as both a central target of disease initiation and an active contributor to disease progression, making a workshop to investigate the role of cell plasticity in lung injury and repair timely. The workshop was organized around four major themes: lung epithelial cell plasticity, signaling control of plasticity, fibroblast plasticity and crosstalk, and translation to human disease. Although this breakdown was recognized to be somewhat artificial, it was felt that this approach would promote cross-fertilization among groups that ordinarily do not communicate and lend itself to the generation of new approaches. The summary reports of individual group discussions below are followed by consensus priorities and recommendations of the workshop participants.
Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials
Blanke, Charles D. , Bot, Brian M. , Thomas, David M. , Köhne, Claus-Henning, Seymour, Michel , Gramont, Aimery de , Goldberg, Richard M. , Sargent, Daniel J. , Bleyer, Archie , Köhne, C.-H., Sargent, Daniel J , Seymour, Matthew T

Mayo Clinic

Journal of Clinical Oncology | June 7, 2011 | Volume: 29 | Issue: 20 | Pages: 2781-2786

10.1200/jco.2010.33.5281 | PMID 21646604 Get It

PurposeColorectal cancer predominantly occurs in the elderly, but approximately 5% of patients are 50 years old or younger. We sought to determine whether young age is prognostic, or whether it influences efficacy/toxicity of chemotherapy, in patients with advanced disease.MethodsWe analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy. End points included progression-free survival (PFS), overall survival (OS), response rate (RR), and grade 3 or worse adverse events. Stratified Cox and adjusted logistic-regression models were used to test for age effects and age-treatment interactions.ResultsA total of 793 patients (13%) were younger than 50 years old; 188 of these patients (3% of total patients) were younger than 40 years old. Grade 3 or worse nausea (10% v 7%; P = .01) was more common, and severe diarrhea (11% v 14%; P = .001) and neutropenia (23% v 26%; P < .001) were less common in young (younger than 50 years) than in older (older than 50 years) patients. Age was prognostic for PFS, with poorer outcomes occurring in those younger than 50 years (median, 6.0 v 7.5 months; hazard ratio, 1.10; P = .02), but it did not affect RR or OS. In the subset of monotherapy versus combination chemotherapy trials, the relative benefits of multiagent chemotherapy were similar for young and older patients. Results were comparable when utilizing an age cut point of 40 years.ConclusionYoung age is modestly associated with poorer PFS but not OS or RR in treated patients with aCRC, and young patients have more nausea but less diarrhea and neutropenia with chemotherapy in general. Young versus older patients derive the same benefits from combination chemotherapy. Absent results of a clinical trial, standard combination chemotherapy approaches are appropriate for young patients with aCRC.